Scopus
🔓 Açık Erişim YÖKSİS Eşleşti
Relations of serum visfatin and resistin levels with endometrial cancer and factors associated with its prognosis
Asian Pacific Journal of Cancer Prevention · Ocak 2015
YÖKSİS Kayıtları
Relations of Serum Visfatin and Resistin Levels with Endometrial Cancer and Factors Associated with its Prognosis
Asian Pacific Journal of Cancer Prevention · 2015 SCI-Expanded
PROFESÖR ALİ ÜNLÜ →
Relations of Serum Visfatin and Resistin Levels with Endometrial Cancer and Factors Associated with its Prognosis
Asian Pacific Journal of Cancer Prevention · 2015 medicus, medline,pubmed
PROFESÖR SETENAY ARZU YILMAZ →
Relations of Serum Visfatin and Resistin Levels with Endometrial Cancer and Factors Associated with its Prognosis
Asian Pacific Journal of Cancer Prevention · 2015 index copernicus, SCOPUS, DOAJ, EMBASE
PROFESÖR ÇETİN ÇELİK →
Relations of Serum Visfatin and Resistin Levels with Endometrial Cancer and Factors Associated with its Prognosis
Asian Pacific Journal of Cancer Prevention · 2015 scopus, IC, ISI, Cite factor, MEDLİNE/PubMed, EMBASE, DOAJ
PROFESÖR ÇETİN ÇELİK →
Relations of Serum Visfatin and Resistin Levels with Endometrial Cancer and Factors Associated with its Prognosis
Asian Pacific Journal of Cancer Prevention · 2015 SCI-Expanded
PROFESÖR ÇETİN ÇELİK →
Relations of Serum Visfatin and Resistin Levels with Endometrial Cancer and Factors Associated with its Prognosis
Asian Pacific Journal of Cancer Prevention · 2015 medicus, medline,pubmed
PROFESÖR ÇETİN ÇELİK →
Relations of Serum Visfatin and Resistin Levels with Endometrial Cancer and Factors Associated with its Prognosis
Asian Pacific Journal of Cancer Prevention · 2015 SCOPUS
PROFESÖR ÇETİN ÇELİK →
Makale Bilgileri
DergiAsian Pacific Journal of Cancer Prevention
Yayın TarihiOcak 2015
Cilt / Sayfa16 · 4503-4508
Scopus ID2-s2.0-84936972270
Erişim🔓 Açık Erişim
Özet
Background: The aims of this study were compare the serum visfatin and resistin levels between endometrial cancer (EC) patients and controls and evaluate their power to predict prognosis. Materials and Methods: This prospective study was conducted between March 2013 to June 2014 on the Gynecologic Oncology Department of the University of Selcuk, Konya, Turkey. A total of 42 EC patients and 42 controls were included and assessed for differences in serum visfatin and resistin levels, along with prognostic factors. Results: Endometrial cancer patients had significantly higher visfatin levels than control s (p: 0.011), associated with deep myometrial invasion (p: 0.019). In contrast the serum level of resistin did not significantly differ between EC patients and controls (p: 0.362). However, high resistin level in EC patients was associated with increase lymph node metastasis (p: 0.009). On logistic regression analysis, we found that serum visfatin elevation was associated with risk of myometrial invasion (OR: 1,091; 95%CI: 1.021- 1.166; p: 0.010) and serum resistin with risk of lymph node metastasis (OR: 1.018; 95%CI: 1.000- 1.035; p: 0.046). For myometrial invasion prediction, a serum visfatin level greater than 26.8 ng/mL demonstrated a sensitivity and specificity of 66.6 % and 96.4%, respectively. For lymph node metastasis prediction, the best cut-off for serum resistin level was 599ng/mL. A serum resistin level greater than this demonstrated a sensitivity and specificity of 87.5% and 77.1%, respectively. Conclusions: Our data suggest that serum visfatin is elevated in patients with EC and serum visfatin and resistin levels could be used to predict the risk of advance stage lesions.
Yazarlar (9)
1
Tolgay Tuyan İlhan
2
Aysegul Kebapcilar
3
Setenay Arzu Yilmaz
4
Turkan Ilhan
5
Özlem Seçilmiş Kerimoğlu
ORCID: 0000-0003-2208-8712
6
Aybike Pekin
7
Fikret Akyürek
8
Ali Ünlü
ORCID: 0000-0002-9991-3939
9
Çetin Çelik
ORCID: 0000-0001-6165-5092
Anahtar Kelimeler
Adipocytokine
Endometrial cancer
Resistin
Visfatin
Kurumlar
Beyhekim State Hospital
Konya Turkey
Selçuk Üniversitesi
Selçuklu Turkey
Metrikler
28
Atıf
9
Yazar
4
Anahtar Kelime